All-trans retinoic acid in hematological malignancies. An update

Stefano Sacchi, Domenico Russo, Giuseppe Awisati, Giuseppe Dastoli, Mario Lazzarino, Pier Giuseppe Pelicci, Mario Regazzi Bonora, Giuseppe Visani, Cinzia Grassi, Isabella Iacona, Lucilla Luzzi, Petronilla Vanzanelli

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background and Objective. During the past ten years, the study of retinoids has undergone a total transformation. The Italian Society of Experimental Hematology decided to discuss these advances at a meeting in Florence on April 18, 1996. Information sources. The material examined in the present review includes articles and abstracts published in journals covered by the Science Citation Index® and Medline®. In addition, all the authors of the present article have been actively working in the field of retinoids and have contributed several papers. Summaries of their oral presentations at the Florence meeting are reported in the Appendix to this review article. State of Art and Perspectives. One of the most important advances has been the elucidation of new molecular mechanisms of control of gene expression by retinoids. A number of new retinoids have been synthesized by chemists, some of which are being screened for potential clinical use, and a few have already had a tremendous impact on clinical practice. The most important achievements have been obtained in acute promyelocytic leukemia. In 1988 a Chinese group working in Shanghai showed that using all-trans retinoic acid (ATRA) alone 94% of acute promyelocytic leukemic patients obtained complete remission through differentiation of the leukemic clone. This result transformed a dream into reality and allowed researchers to move from laboratory experience to clinical applications of this differentiating therapy. Expanding the spectrum of hematological malignancies that may respond to ATRA remains a challenge; however, several results show some activity of retinoids alone or in combination with other drugs in juvenile chronic myeloid leukemia (CML), myelodysplastic syndrome, cutaneous T-cell lymphoma and CML. Particularly interesting are the studies that explored the potential clinical synergism of ATRA-based combination therapies with growth factors, other differentiating agents such as vitamin D3, immunomodulators like interferons, or chemotherapeutic agents, in particular Ara-C, all of which show promising in vitro effects when used in combination with retinoids.

Original languageEnglish
Pages (from-to)106-121
Number of pages16
JournalHaematologica
Volume82
Issue number1
Publication statusPublished - Jan 1997

Fingerprint

Retinoids
Hematologic Neoplasms
Tretinoin
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cutaneous T-Cell Lymphoma
Acute Promyelocytic Leukemia
Cholecalciferol
Myelodysplastic Syndromes
Cytarabine
Immunologic Factors
Hematology
Interferons
Intercellular Signaling Peptides and Proteins
Clone Cells
Research Personnel
Gene Expression
Therapeutics
Pharmaceutical Preparations

Keywords

  • ATRA
  • Hematological malignancies

ASJC Scopus subject areas

  • Hematology

Cite this

Sacchi, S., Russo, D., Awisati, G., Dastoli, G., Lazzarino, M., Pelicci, P. G., ... Vanzanelli, P. (1997). All-trans retinoic acid in hematological malignancies. An update. Haematologica, 82(1), 106-121.

All-trans retinoic acid in hematological malignancies. An update. / Sacchi, Stefano; Russo, Domenico; Awisati, Giuseppe; Dastoli, Giuseppe; Lazzarino, Mario; Pelicci, Pier Giuseppe; Bonora, Mario Regazzi; Visani, Giuseppe; Grassi, Cinzia; Iacona, Isabella; Luzzi, Lucilla; Vanzanelli, Petronilla.

In: Haematologica, Vol. 82, No. 1, 01.1997, p. 106-121.

Research output: Contribution to journalArticle

Sacchi, S, Russo, D, Awisati, G, Dastoli, G, Lazzarino, M, Pelicci, PG, Bonora, MR, Visani, G, Grassi, C, Iacona, I, Luzzi, L & Vanzanelli, P 1997, 'All-trans retinoic acid in hematological malignancies. An update', Haematologica, vol. 82, no. 1, pp. 106-121.
Sacchi S, Russo D, Awisati G, Dastoli G, Lazzarino M, Pelicci PG et al. All-trans retinoic acid in hematological malignancies. An update. Haematologica. 1997 Jan;82(1):106-121.
Sacchi, Stefano ; Russo, Domenico ; Awisati, Giuseppe ; Dastoli, Giuseppe ; Lazzarino, Mario ; Pelicci, Pier Giuseppe ; Bonora, Mario Regazzi ; Visani, Giuseppe ; Grassi, Cinzia ; Iacona, Isabella ; Luzzi, Lucilla ; Vanzanelli, Petronilla. / All-trans retinoic acid in hematological malignancies. An update. In: Haematologica. 1997 ; Vol. 82, No. 1. pp. 106-121.
@article{f540ea3c8fc548599838cb35a35fb081,
title = "All-trans retinoic acid in hematological malignancies. An update",
abstract = "Background and Objective. During the past ten years, the study of retinoids has undergone a total transformation. The Italian Society of Experimental Hematology decided to discuss these advances at a meeting in Florence on April 18, 1996. Information sources. The material examined in the present review includes articles and abstracts published in journals covered by the Science Citation Index{\circledR} and Medline{\circledR}. In addition, all the authors of the present article have been actively working in the field of retinoids and have contributed several papers. Summaries of their oral presentations at the Florence meeting are reported in the Appendix to this review article. State of Art and Perspectives. One of the most important advances has been the elucidation of new molecular mechanisms of control of gene expression by retinoids. A number of new retinoids have been synthesized by chemists, some of which are being screened for potential clinical use, and a few have already had a tremendous impact on clinical practice. The most important achievements have been obtained in acute promyelocytic leukemia. In 1988 a Chinese group working in Shanghai showed that using all-trans retinoic acid (ATRA) alone 94{\%} of acute promyelocytic leukemic patients obtained complete remission through differentiation of the leukemic clone. This result transformed a dream into reality and allowed researchers to move from laboratory experience to clinical applications of this differentiating therapy. Expanding the spectrum of hematological malignancies that may respond to ATRA remains a challenge; however, several results show some activity of retinoids alone or in combination with other drugs in juvenile chronic myeloid leukemia (CML), myelodysplastic syndrome, cutaneous T-cell lymphoma and CML. Particularly interesting are the studies that explored the potential clinical synergism of ATRA-based combination therapies with growth factors, other differentiating agents such as vitamin D3, immunomodulators like interferons, or chemotherapeutic agents, in particular Ara-C, all of which show promising in vitro effects when used in combination with retinoids.",
keywords = "ATRA, Hematological malignancies",
author = "Stefano Sacchi and Domenico Russo and Giuseppe Awisati and Giuseppe Dastoli and Mario Lazzarino and Pelicci, {Pier Giuseppe} and Bonora, {Mario Regazzi} and Giuseppe Visani and Cinzia Grassi and Isabella Iacona and Lucilla Luzzi and Petronilla Vanzanelli",
year = "1997",
month = "1",
language = "English",
volume = "82",
pages = "106--121",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - All-trans retinoic acid in hematological malignancies. An update

AU - Sacchi, Stefano

AU - Russo, Domenico

AU - Awisati, Giuseppe

AU - Dastoli, Giuseppe

AU - Lazzarino, Mario

AU - Pelicci, Pier Giuseppe

AU - Bonora, Mario Regazzi

AU - Visani, Giuseppe

AU - Grassi, Cinzia

AU - Iacona, Isabella

AU - Luzzi, Lucilla

AU - Vanzanelli, Petronilla

PY - 1997/1

Y1 - 1997/1

N2 - Background and Objective. During the past ten years, the study of retinoids has undergone a total transformation. The Italian Society of Experimental Hematology decided to discuss these advances at a meeting in Florence on April 18, 1996. Information sources. The material examined in the present review includes articles and abstracts published in journals covered by the Science Citation Index® and Medline®. In addition, all the authors of the present article have been actively working in the field of retinoids and have contributed several papers. Summaries of their oral presentations at the Florence meeting are reported in the Appendix to this review article. State of Art and Perspectives. One of the most important advances has been the elucidation of new molecular mechanisms of control of gene expression by retinoids. A number of new retinoids have been synthesized by chemists, some of which are being screened for potential clinical use, and a few have already had a tremendous impact on clinical practice. The most important achievements have been obtained in acute promyelocytic leukemia. In 1988 a Chinese group working in Shanghai showed that using all-trans retinoic acid (ATRA) alone 94% of acute promyelocytic leukemic patients obtained complete remission through differentiation of the leukemic clone. This result transformed a dream into reality and allowed researchers to move from laboratory experience to clinical applications of this differentiating therapy. Expanding the spectrum of hematological malignancies that may respond to ATRA remains a challenge; however, several results show some activity of retinoids alone or in combination with other drugs in juvenile chronic myeloid leukemia (CML), myelodysplastic syndrome, cutaneous T-cell lymphoma and CML. Particularly interesting are the studies that explored the potential clinical synergism of ATRA-based combination therapies with growth factors, other differentiating agents such as vitamin D3, immunomodulators like interferons, or chemotherapeutic agents, in particular Ara-C, all of which show promising in vitro effects when used in combination with retinoids.

AB - Background and Objective. During the past ten years, the study of retinoids has undergone a total transformation. The Italian Society of Experimental Hematology decided to discuss these advances at a meeting in Florence on April 18, 1996. Information sources. The material examined in the present review includes articles and abstracts published in journals covered by the Science Citation Index® and Medline®. In addition, all the authors of the present article have been actively working in the field of retinoids and have contributed several papers. Summaries of their oral presentations at the Florence meeting are reported in the Appendix to this review article. State of Art and Perspectives. One of the most important advances has been the elucidation of new molecular mechanisms of control of gene expression by retinoids. A number of new retinoids have been synthesized by chemists, some of which are being screened for potential clinical use, and a few have already had a tremendous impact on clinical practice. The most important achievements have been obtained in acute promyelocytic leukemia. In 1988 a Chinese group working in Shanghai showed that using all-trans retinoic acid (ATRA) alone 94% of acute promyelocytic leukemic patients obtained complete remission through differentiation of the leukemic clone. This result transformed a dream into reality and allowed researchers to move from laboratory experience to clinical applications of this differentiating therapy. Expanding the spectrum of hematological malignancies that may respond to ATRA remains a challenge; however, several results show some activity of retinoids alone or in combination with other drugs in juvenile chronic myeloid leukemia (CML), myelodysplastic syndrome, cutaneous T-cell lymphoma and CML. Particularly interesting are the studies that explored the potential clinical synergism of ATRA-based combination therapies with growth factors, other differentiating agents such as vitamin D3, immunomodulators like interferons, or chemotherapeutic agents, in particular Ara-C, all of which show promising in vitro effects when used in combination with retinoids.

KW - ATRA

KW - Hematological malignancies

UR - http://www.scopus.com/inward/record.url?scp=17544392708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17544392708&partnerID=8YFLogxK

M3 - Article

C2 - 9107096

AN - SCOPUS:17544392708

VL - 82

SP - 106

EP - 121

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -